The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Micky I’m not sure I agree. This will come good and has done already. You had the chance to sell but git greedy thinking it would boom. Syme, Hemo… etc you are trying to get rich quick and it can go either way. If Yiu want a less stress free investment life look at FTSE 100 companies. GL
I am convinced that a surprise will come soon with regards to funding. i just have a feeling that one of the big boys will chuck some money in with milestone payments to follow.
This is cheap for everyone at the minute even them. someone could get on board for 10's of millions instead of hundreds. all this needs is one bit of positive news and boom.
Absolutely no idea anymore, I would have had a bet for a 100k with anyone that this share would never see the 1’s again but here we are. Two things I do know.
1: I should have listened to my mate who makes a fortune investing when he told me to sell.
2: I don’t listen.
I don’t think it will take much to get this going, I do think that once trials start this will get going again. It hey what do I know. GLA
And this,
Here is something to consider over the weekend regarding a potential global licencing deal and the impact that it would have on the Hemogenyx share price.
* In the last 12 months, according to JP Morgan, these have been the biggest licencing deals in our sector:
* Akeso paid $500 million upfront by Summit Therapeutics in 2023 to in-license ivonescimab. Additionally, the partnership outlines a potential deal value of up to USD 4.5 billion.
* Alnylam received an upfront cash payment of USD 310 million from Roche in 2023 to co-develop and co-commercialize Zilebesiran. Additional development, regulatory, and sales milestones could potentially elevate the deal value to USD 2.8 billion.
* Evotec paid $50 Million upfront in 2023 by Bristol Myers Squibb. Tiered royalties on product sales further underscore the financial commitment, resulting in USD 4bn potential deal value.
* Kelun-Biotech paid an upfront $175 Million by Merck in 2023 to co-develop preclinical antibody-drug conjugates. Future development, regulatory, and sales milestone payments, which could total up to USD 9.3 billion.
In the £Billions according to PWC. They are predicting a "return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps"....
Amgen purchased Horizon Therapeutics for $27.8 Billion (yes, 27.8 Billion),
Pfizer acquired Global Blood Therapeutics for $5.4Billion
Pfizer bought Biohaven Pharmaceutical for $11.6 Billion in Cash,
Affinivax bought by GSK for $ 2.10Billion,
AstraZeneca acquired CinCor Pharma for $1.8 Billion,
Thermo Fisher Acquired PeproTech for $1.85 Billion,
Pfizer bought Arena for £6.7 Billion,
AZ paid 1 billion for KYM Bio,
AZ paid $2 Billion to partner Quell Therapeutics,
Lilly’s acquired Versanis for $1.925 billion,
SOBiovitrum’s CTI Bio deal was for $1.7 billion,
Astellas bought Iveric Bio for $5.9billion,
GSK's paid £1.6Billion to buy Bellus....
One day we will wake up to an RNS announcing something similar to the deals noted above. Next stop though is probably a licencing deal. The good news is that in 2023 the average licencing deal was for $47 Million.
“Executives will continue to deploy cash balances and seek out areas of innovation and clinical differentiation,” PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. “As regulators’ perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps.”
Source: https://www.fiercepharma.com/pharma/2024-forecast-ma-saw-uptick-2023-expect-trend-continue
Good God i wish my average was 2p, what an opportunity to make dosh. this has to be the low and with Cart-T fully funded to start phase 1 and CBR and CDX going in the back ground I expect another investment soon. once this is even slightly proven to be safe this will explode. this has more upside than Avacta and nothing is priced in here.
GLA.
It’s very strange how everyone is transfixed on Cart-T and the CBR. Stuff in the back ground is being overlooked. If this company had no Cart-T product whatsoever this should still be above 2p. It’s up up up from here.